Iterum Therapeutics plc (ITRMF) Total Non-Current Liabilities (2017 - 2024)

Iterum Therapeutics' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $48.7 million for Q4 2024.

• In Q4 2024, Total Non-Current Liabilities rose 49.89% year-over-year to $48.7 million; the TTM figure through Dec 2024 stood at $48.7 million (up 49.89% YoY), while the FY2024 annual figure was $48.7 million, up 49.89% from the prior year.
• Total Non-Current Liabilities for Q4 2024 stood at $48.7 million, up from $25.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $78.7 million in Q1 2021, with the low at $25.1 million in Q2 2024.
• The 5-year median for Total Non-Current Liabilities is $37.9 million (2023), against an average of $47.6 million.
• The sharpest annual moves came in 2020 and 2022: Total Non-Current Liabilities soared 158.43% in 2020, then slumped 59.1% in 2022.
• Iterum Therapeutics' Total Non-Current Liabilities stood at $77.5 million in 2020, then tumbled by 51.21% to $37.8 million in 2021, then dropped by 0.82% to $37.5 million in 2022, then slipped by 13.47% to $32.5 million in 2023, then soared by 49.89% to $48.7 million in 2024.
• Business Quant data shows ITRMF's Total Non-Current Liabilities at $48.7 million in Q4 2024, $25.1 million in Q2 2024, and $25.7 million in Q1 2024.